Coadministration of carvedilol attenuates nitrate tolerance by preventing cytochrome P450 depletion

Circulation Journal

Volumn 74, Issue 8, 2010, Pages 1711-1717

  Nakahira, Atsushi ^a   Minamiyama, Yukiko ^a,b   Takemura, Shigekazu ^a   Hirai, Hidekazu ^a   Sasaki, Yasuyuki ^a   Okada, Shigeru ^b   Funae, Yoshihiko ^a   Suehiro, Shigefumi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Carvedilol; Cytochrome P450; Nitrate tolerance; Oxidative stress

Indexed keywords

CARVEDILOL; CYCLIC GMP; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; GLYCERYL TRINITRATE; MIRISROL; NITRATE; NITRIC OXIDE; SERINE; SUPEROXIDE; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA WALL; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME INHIBITION; HEART; HEMODYNAMICS; MALE; MONOTHERAPY; NONHUMAN; PROTEIN DEPLETION; PROTEIN SYNTHESIS INHIBITION; RAT; SIGNAL TRANSDUCTION; WISTAR RAT;

ANIMALS; CARBAZOLES; CELL ADHESION MOLECULES; CYCLIC GMP; CYTOCHROME P-450 ENZYME SYSTEM; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FREE RADICALS; MALE; MICROFILAMENT PROTEINS; NITRIC OXIDE; NITROGLYCERIN; PHOSPHOPROTEINS; PROPANOLAMINES; RATS; SUPEROXIDES;

EID: 77955061157     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0149     Document Type: Article

References (37)

1. Nishiyama K, Tsutamoto T, Yamaji M, Kawahara C, Yamamoto T, Fujii M, et al. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure: Special reference to transcar-diac gradient of norepinephrine. Circ J 2009; 73: 2270-2275.
2. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators. Circulation 1996; 94: 2807-2816.
3. Kataoka M, Satoh T, Yoshikawa T, Nakamura I, Kohno T, Yoshizawa A, et al. Comparison of the effects of carvedilol andmetoprolol on exercise ventilatory effciency in patients with congestive heart failure. Circ J 2008; 72: 358-363.
4. Hirooka K, Yasumura Y, Ishida Y, Hanatani A, Nakatani S, Komamura K, et al. Comparative left ventricular functional and neu-rohumoral effects of chronic treatment with carvedilol versus meto-prolol in patients with dilated cardiomyopathy. Jpn Circ J 2001; 65: 931-936.
5. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362: 7-13.
6. Jonsson G, Abdelnoor M, Seljefot I, Arnesen H, Hostmark AT, Kjeldsen SE, et al. The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. J Cardiovasc Pharmacol 2007; 49: 27-32.
7. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Preventive effects of carvedilol on nitrate tolerance: A randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol 1998; 32: 1201-1206.
8. Kametani R, Miura T, Harada N, Shibuya M, Wang R, Tan H, et al. Carvedilol inhibits mitochondrial oxygen consumption and super-oxide production during calcium overload in isolated heart mitochondria. Circ J 2006; 70: 321-326.
9. Cargnoni A, Ceconi C, Bernocchi P, Boraso A, Parrinello G, Curello S, et al. Reduction of oxidative stress by carvedilol: Role in maintenance of ischaemic myocardium viability. Cardiovasc Res 2000; 47: 556-566.
10. Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carve-dilol in cardiovascular disease. J Hypertension 2007; 25: 731-741.
11. Kono Y, Nakamura K, Kimura H, Nishii N, Watanabe A, Banba K, et al. Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. Circ J 2006; 70: 1001-1005.
12. Kritharides L, Stocker R. The use of antioxidant supplements in coronary heart disease. Atherosclerosis 2002; 164: 211-219.
13. Kojima S, Matsui K, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, et al. Long-term nitrate therapy after acute myocardial infarction does not improve or aggravate prognosis. Circ J 2007; 71: 301-307.
14. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Effcacy and rebound phenomenon related to intermittent nitroglycerin therapy for the prevention of nitrate tolerance. Jpn Circ J 1998; 62: 571-575.
15. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Preventive effects of angiotensin-converting enzyme inhibitors on nitrate tolerance during continuous transdermal application of nitroglycerin in patients with chronic heart failure. Jpn Circ J 1998; 62: 353-358.
16. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J Am Coll Cardiol 1998; 32: 1194-1200.
17. Parker JD. Therapy with nitrates: Increasing evidence of vascular toxicity. J Am Coll Cardiol 2003; 42: 1835-1837.
18. Minamiyama Y, Takemura S, Hai S, Suehiro S, Okada S. Vitamin E defciency accelerates nitrate tolerance via a decrease in cardiac P450 expression and increased oxidative stress. Free Radic Biol Med 2006; 40: 808-816.
19. Gori T, Mak SS, Kelly S, Parker JD. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J Am Coll Cardiol 2001; 38: 1096-1101.
20. Sydow K, Daiber A, Oelze M, Chen Z, August M, Wendt M, et al. Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 2004; 113: 482-489.
21. Minamiyama Y, Imaoka S, Takemura S, Okada S, Inoue M, Funae Y. Escape from tolerance of organic nitrate by induction of cyto-chrome P450. Free Radic Biol Med 2001; 31: 1498-1508.
22. McDonald BJ, Bennett BM. Biotransformation of glyceryl trini-trate by rat aortic cytochrome P450. Biochem Pharmacol 1993; 45: 268-270.
23. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res 2005; 97: 618-628.
24. Mulsch A, Oelze M, Kloss S, Mollnau H, Topfer A, Smolenski A, et al. Effects of in vivo nitroglycerin treatment on activity and expression of the guanylyl cyclase and cGMP-dependent protein kinase and their downstream target vasodilator-stimulated phos-phoprotein in aorta. Circulation 2001; 103: 2188-2194.
25. Kato K, Iinuma H, Inagaki Y, Kanazawa T, Kawai T, Kishida H, et al. Randomized, double-blind, placebo-controlled study of carve-dilol on angina pectoris. Rinsyo To Kenkyu 1990; 67: 618-631.
26. Munzel T, Wenzel P, Daiber A. Do we still need organic nitrates? J Am Coll Cardiol 2007; 49: 1296-1298.
27. Thomas GR, DiFabio JM, Gori T, Parker JD. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: Evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 2007; 49: 1289-1295.
28. Daiber A, Mulsch A, Hink U, Mollnau H, Warnholtz A, Oelze M, et al. The oxidative stress concept of nitrate tolerance and the anti-oxidant properties of hydralazine. Am J Cardiol 2005; 96: 25i-36i.
29. Elkayam U, Johnson JV, Shotan A, Bokhari S, Solodky A, Canetti M, et al. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation 1999; 99: 2652-2657.
30. Munzel T, Mollnau H, Hartmann M, Geiger C, Oelze M, Warnholtz A, et al. Effects of a nitrate-free interval on tolerance, vasoconstrictor sensitivity and vascular superoxide production. J Am Coll Cardiol 2000; 36: 628-634.
31. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989; 13: 786-795.
32. Gutterman DD. Combating nitrate tolerance: A novel endogenous mechanism. Arterioscler Thromb Vasc Biol 2007; 27: 1673-1676.
33. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation 1997; 96: 2545-2550.
34. Minamiyama Y, Takemura S, Akiyama T, Imaoka S, Inoue M, Funae Y, et al. Isoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels. FEBS Lett 1999; 452: 165-169.
35. Mihm MJ, Coyle CM, Jing L, Bauer JA. Vascular peroxynitrite formation during organic nitrate tolerance. J Pharmacol Exp Ther 1999; 291: 194-198.
36. Hink U, Oelze M, Kolb P, Bachschmid M, Zou MH, Daiber A, et al. Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance. J Am Coll Cardiol 2003; 42: 1826-1834.
37. Oldham HG, Clarke SE. In vitro identifcation of the human cyto-chrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos 1997; 25: 970-977.